THIS IS THE SVF-2

The SVF-2 presents a major step forward for cellular therapy. In as little as 60 minutes, a small sample of tissue is used to create a cellular implant for targeted therapy.

SVF-2 Illustration

INTRODUCING THE SVF-2

The SVF-2 uniquely harvests and isolates a patient’s own stromal and vascular cells, including stromal progenitor cells, to help control pain, reduce inflammation and repair inflamed tissues in the osteoarthritic knee.  FDA Phase II clinical trials for this minimally invasive procedure have shown no serious adverse events and significant improvements in pain, stiffness and function (see results of the clinical study here: AJSM Phase IIb ).

svf-2

MUSCULOSKELETAL THERAPIES

Therapies designed to reduce pain and improve mobility using cellular implants of your own cells.

Globe Clipart

COMING SOON

Further clinical trials are already or will soon be underway to prove the SVF-2’s effectiveness in the treatment of osteoarthritis and rheumatoid arthritis throughout the body.

PENDING APPROVAL

The SVF-2 has been proven effective in the treatment of osteoarthritis in the knee and has been submitted to the FDA for approval.

DERMAL THERAPIES

Repair and reconstruct dermal tissues such as non-healing wounds and diabetic foot ulcers resulting from peripheral vascular disease/diabetes.

COMING SOON

Clinical trials of the SVF-2ʼs effectiveness in treating peripheral vascular disease in small & large vessels, diabetic ulcers, and volume augmentation have already been completed, with more coming soon.

COMING SOON

Trials in long covid, CPD, and kidney fibrosis are already underway.

ORGAN THERAPIES

Repair vascular organ function with cellular therapies being developed to address fibrosis and ischemia in lungs, kidneys, and the liver.

PIPELINE OVERVIEW

PRE-CLINICAL

SAFETY/FEASIBILITY

PIVOTAL SAFETY/EFFICACY

FDA MARKET APPROVAL

The osteoarthritis trial is a multi-site pivotal clinical trial that is double-blinded, randomized, placebo-controlled, dose-escalated, and statistically powered. The trial has IDE and is compliant with FDA regulations.

Clinical trials for diabetic ulcers and wounds are safety and feasibility studies.

A safety/feasibility clinical trial to assess use of SVF for treatment of long covid. The trial has IDE approval by the FDA.

The COPD trial is an exploratory clinical trial to assess initial safety and feasibility of SVF for treatment of COPD.

This trial is an exploratory clinical trial to assess initial safety and feasibility of SVF for treatment of rheumatoid arthritis and osteoarthritis of the hands/fingers.

PRE-CLINICAL

FEASIBILITY SAFETY/EFFICACY

PIVOTAL SAFETY/EFFICACY

FDA MARKET APPROVAL

THIS IS THE SVF-2

The SVF-2 presents a major step forward for cellular therapy. In as little as 60 minutes, a small sample of tissue is used to create a cellular implant for targeted therapy.

SVF-2 Illustration
svf-2

INTRODUCING THE SVF-2

The SVF-2 uniquely harvests and isolates a patient’s own stromal and vascular cells, including stromal progenitor cells, to help control pain, reduce inflammation and repair inflamed tissues in the osteoarthritic knee.  FDA Phase II clinical trials for this minimally invasive procedure have shown no serious adverse events and significant improvements in pain, stiffness and function (see results of the clinical study here: AJSM Phase IIb ).

MUSCULOSKELETAL THERAPIES

Therapies designed to reduce pain and improve mobility using cellular implants of your own cells.

COMING SOON

Further clinical trials are already or will soon be underway to prove the SVF-2’s effectiveness in the treatment of osteoarthritis and rheumatoid arthritis throughout the body.

PENDING APPROVAL

The SVF-2 has been proven effective in the treatment of osteoarthritis in the knee and has been submitted to the FDA for approval.

DERMAL THERAPIES

Repair and reconstruct dermal tissues such as non-healing wounds and diabetic foot ulcers resulting from peripheral vascular disease/diabetes.

COMING SOON

Clinical trials of the SVF-2ʼs effectiveness in treating peripheral vascular disease in small & large vessels, diabetic ulcers, and volume augmentation have already been completed, with more coming soon.

ORGAN THERAPIES

Repair vascular organ function with cellular therapies being developed to address fibrosis and ischemia in lungs, kidneys, and the liver.

COMING SOON

Trials in long covid, CPD, and kidney fibrosis are already underway.

The osteoarthritis trial is a multi-site pivotal clinical trial that is double-blinded, randomized, placebo-controlled, dose-escalated, and statistically powered. The trial has IDE and is compliant with FDA regulations.

Clinical trials for diabetic ulcers and wounds are safety and feasibility studies.

A safety/feasibility clinical trial to assess use of SVF for treatment of long covid. The trial has IDE approval by the FDA.

The COPD trial is an exploratory clinical trial to assess initial safety and feasibility of SVF for treatment of COPD.

This trial is an exploratory clinical trial to assess initial safety and feasibility of SVF for treatment of rheumatoid arthritis and osteoarthritis of the hands/fingers.